+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Montelukast Sodium Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4997515
  • Report
  • March 2020
  • Region: Global
  • 110 pages
  • Mordor Intelligence
1 of 4

FEATURED COMPANIES

  • Apotex Inc
  • Cipla Limited
  • Delmar Chemicals Inc.
  • Intas Pharmaceuticals Ltd
  • Merck & Co., Inc.
  • Morepen Laboratories
  • MORE
The montelukast sodium market studied was projected to grow with a CAGR of nearly 12.6% over the forecast period. The major factor attributing to the growth of the market is the increase in the prevalence of diseases such asthma, exercise induced bronchospasm, allergic rhinitis, primary dysmenorrhea and urticaria.

According to the World Health Organization, around 235 million people are living with asthma. Over 80% of asthma-related deaths occur in low-and lower-middle income countries. As the number of patients increases the demand for montelukast sodium also rises. However, side effects with the product such as stomach pain, heartburn, upset stomach, nausea, and diarrhea constraints the market growth.

Key Market Trends

Asthma Segment is Found Dominating the Montelukast Sodium Market

Montelukast sodium is used to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma in adults and children 12 months of age and older. With the growing prevalence of asthma globally, the usage of montelukast sodium also increases. According to the Centers for Disease Control and Prevention (CDC), 1 in 13 people have asthma. More than 25 million Americans have asthma, that is 7.7 percent of adults and 8.4 percent of children, in 2017. There are about 6.2 million children under the age of 18 with asthma. Asthma accounts for 9.8 million doctor’s office visits, 188,968 discharges from hospital inpatient care and 1.8 million emergency department visits each year. Hence with the rising incidence and prevalence of asthma it is expected to increase the demand of montelukast sodium resulting into the high growth of the market.

North America Found Dominating the Montelukast Sodium Market

North America is expected to dominate the overall market, due to the factors such as the presence of key players, high prevalence of asthma and other respiratory diseases, established healthcare infrastructure are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and increase in number of research partnerships are some of the drivers expected to increase the market growth.

In this region the United States has the maximum share due to supportive healthcare policies, high number of patients, and a developed healthcare market. According to Centres for Disease Control, in 2017, around 8.1 percent of the population of the United States currently had asthma. As per the statistics the the increasing patient pool and increasing disposable revenue in this country boosts the market growth of the region.

Competitive Landscape

The Montelukast Sodium market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Merck & Co., Inc., Morepen Laboratories, Teva Pharmaceuticals USA, Inc., Mylan N.V., Cipla Limited, Intas Pharmaceuticals Ltd, SUN PHARMA, Apotex Inc, SANYO CHEMICAL INDUSTRIES LTD, Delmar Chemicals Inc.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Apotex Inc
  • Cipla Limited
  • Delmar Chemicals Inc.
  • Intas Pharmaceuticals Ltd
  • Merck & Co., Inc.
  • Morepen Laboratories
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Disease like Asthma, Allergic Rhinitis, etc.
4.2.2 Rise in Geriatric Population
4.3 Market Restraints
4.3.1 Side Effects of the Product
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Dosage Form
5.1.1 Tablets
5.1.2 Oral Solutions
5.2 By Application
5.2.1 Asthma
5.2.2 Allergic Rhinitis
5.2.3 Urticaria
5.2.4 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Rest of the World

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Merck & Co., Inc.
6.1.2 Morepen Laboratories
6.1.3 Teva Pharmaceuticals USA, Inc.
6.1.4 Mylan N.V.
6.1.5 Cipla Limited
6.1.6 Intas Pharmaceuticals Ltd
6.1.7 SUN PHARMA
6.1.8 Apotex Inc
6.1.9 SANYO CHEMICAL INDUSTRIES LTD
6.1.10 Delmar Chemicals Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Merck & Co., Inc.
  • Morepen Laboratories
  • Teva Pharmaceuticals USA, Inc.
  • Mylan N.V.
  • Cipla Limited
  • Intas Pharmaceuticals Ltd
  • SUN PHARMA
  • Apotex Inc
  • SANYO CHEMICAL INDUSTRIES LTD
  • Delmar Chemicals Inc.
Note: Product cover images may vary from those shown
Adroll
adroll